Product Information for Vets -
An aqueous suspension for subcutaneous injection. One dose (5 ml) of the vaccine contains at least 105.5 TCID50 inactivated Bovine Respiratory Syncytial virus (strain EV 908) and at least 107.3 TCID50 Parainfluenza-3- virus (strain SF-4 Reisinger), together with 9 x 109 cells inactivated Mannheimia haemolytica bacteria (serotype A1) propagated under conditions of iron restriction. Aluminium hydroxide and Quil A are included as adjuvants. Sodium timerfonate is included as a preservative.
For the active immunisation of cattle against
- Parainfluenza3 virus (PI3 virus), to reduce infections.
- Bovine Respiratory Syncytial Virus (BRSV) to reduce infection and clinical signs.
- Mannheimia haemolytica serotype A1, to reduce infection, mortality, clinical signs, lung lesions and bacterial invasion of the lung caused by serotypes A1 and A6.
The double adjuvant in Bovipast RSP, combined with inactivated bovine RSV, provides a significant step forward in RSV control – even in the face of MDA. The patented IRP (iron regulated protein) technology in Bovipast RSP allows the vaccinated animal to mount a defence against Mannheimia haemolytica earlier in the cycle of bacterial attack than either traditional or leucotoxin vaccines. The same IRPs exist in other serotypes, including A6.
For uses, dosage, contra-indications and warnings please consult the Summary of Product Characteristics (SPC) or your veterinary supplier. Further information is available on request. Use medicines responsibly.
50 ml bottle (10 doses)